- JP-listed companies
- Renascience Inc.
- Ownership
Renascience Inc. (4889) Shareholders
Market cap
¥20.7B
P/E ratio
-37.6x
Rena Science develops pharmaceuticals, medical devices, and AI-powered software to address critical health challenges including cancer, diabetes, and age-related diseases.
大株主
| （単位：千株） | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 |
|---|---|---|---|---|---|
| 特定有価証券信託受託者 株式会社SMBC信託銀行 | 4,738.6 37.28% | 4,738.6 37.28% | 4,738.6 37.28% | 4,360.6 34.3% | 4,360.6 31.65% |
| 宮 田 敏 男 | 1,470.7 10.68% | ||||
| 上田八木短資 | 259.2 2.04% | 300 2.18% | |||
| BNYM SA／NV FOR BNYM FOR BNYM GCM CLIENT ACCTS M ILM FE | 276.1 2% | ||||
| BOFAS INC SEGREGATION ACCOUNT | 263.4 1.91% | ||||
| 楽天証券株式会社共有口 | 189.8 1.38% | ||||
| 林 田 広 明 | 173 1.26% | ||||
| 第一リアルター | 156.9 1.14% | ||||
| SBI証券 | 226.392 1.78% | 53.18 0.42% | 80.54 0.63% | 96.286 0.76% | 150.621 1.09% |
| 飯 田 晋 一 | 64.3 0.47% | ||||
| 宮田 敏男 | 1,420 11.17% | 1,470.7 11.57% | |||
| 大和日台バイオベンチャー投資事業有限責任組合 | 1,647.3 12.96% | 1,647.3 12.96% | 1,257.8 9.89% | 652.3 5.13% | |
| モルガン・スタンレーMUFG証券 | 154.9 1.22% | ||||
| BNY GCM CLIENT ACCOUNT JPRD AC ISG | 177 1.39% | 141 1.11% | 84.1 0.66% | ||
| 加 藤 大 輔 | 59.1 0.46% | ||||
| 松井証券 | 91.8 0.72% | 57.9 0.46% | |||
| 清 田 英 治 | 57.1 0.45% | ||||
| 篠 原 まゆみ | 51.9 0.41% | ||||
| 小林 貫太 | 77.7 0.61% | ||||
| JPモルガン証券 | 95.3 0.75% | 72.5 0.57% | |||
| 駒瀬 丈郎 | 66.2 0.52% | 68 0.53% | |||
| 山口 義道 | 66 0.52% | ||||
| 宮田敏男 | 1,420 11.17% | 1,420 11.17% | |||
| SMBC社会課題解決投資事業有限責任組合 | 150 1.18% | 150 1.18% | |||
| 77ニュービジネス投資事業有限責任組合 | 61.2 0.48% | ||||
| BARCLAYS CAPITAL SECURITIES LIMITED | 58 0.46% | ||||
| 楽天証券 | 212.3 1.67% | ||||
| KSP5号投資事業有限責任組合 | 120 0.94% | ||||
| SBIネオトレード証券 | 83.4 0.66% | ||||
| 日本証券金融 | 74.5 0.59% | ||||
| 計 | 8,764.292 68.95% | 8,466.78 66.61% | 8,181.34 64.36% | 7,044.886 55.42% | 7,405.421 53.76% |